Overview
- University of Eastern Finland researchers report that lithium chloride reduced phosphorylation at known Tau sites and uncovered new Alzheimer’s‑relevant sites in two cell models using proteomics.
- Across the datasets, the compound acted on GSK‑3β, a kinase that drives abnormal Tau changes, and the analyses point to effects on other kinases involved in the same process.
- The team also found shifts in Rho GTPase signaling, a control system for cell shape and transport that some studies have linked to Alzheimer’s biology.
- Clinical trials of lithium salts have shown mixed cognitive results, which a recent US study suggests may stem from inorganic salts binding to amyloid plaques and lowering effective brain levels.
- The authors call for animal studies and careful testing of alternative lithium formulations to learn whether these cell‑level effects can translate into meaningful benefits for patients.